In a randomized, placebo-controlled trial of neuromyelitis optica spectrum disorder patients, satralizumab monotherapy demonstrated a decrease in relapse rate when compared to placebo. In a randomized, open-label, multicenter trial of tocilizumab vs. azathioprine, treatment with tocilizumab demonstrated a decreased risk of a relapse compared to azathioprine.
ABSTRACT & COMMENTARY
Clinical Trials of IL-6 Inhibitors for the Treatment of Neuromyelitis Optica Spectrum Disorders
August 1, 2020